Notably, many of the pathways associated with MRlncRNAs—including Wnt/β-catenin, mTOR, and MAPK—are well-established drivers of HCC progression and therapeutic resistance, as highlighted in recent reviews (Altaf et al., 2022). The gene discussed is MTOR; the disease is hepatocellular carcinoma.